# Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

> **NCT05814770** · PHASE4 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 96 (estimated)

## Conditions studied

- Primary Aldosteronism
- Hypertension

## Interventions

- **DRUG:** Finerenone
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT05814770
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05
- **Primary completion:** 2025-03
- **Final completion:** 2026-03
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814770, "Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05814770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*